Burnham & Co’s Novo Nordisk NVO Stock Holding History

Burnham & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200	Closed	-$7.35K	–	204
2026 Q1	$7.35K	Buy	+200	New	+$9.48K	0.01%	173

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Burnham & Co's NVO Position: Q2 2026 in Review

Burnham & Co sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 200 shares — an estimated $7.35K sold.

Burnham & Co first reported a position in NVO in Q1 2026 and held it in 1 quarter. The position peaked at $7.35K in Q1 2026. 1,363 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Burnham & Co reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
Burnham & Co sold 200 Novo Nordisk shares in Q2 2026, an estimated $7.35K.
Burnham & Co first reported a position in Novo Nordisk in Q1 2026 and held it in 1 quarter.
Burnham & Co's Novo Nordisk position peaked at $7.35K in Q1 2026.
1,363 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Burnham & Co's 13F filing for Q2 2026, filed 11 Aug 2026.